| Autor: |
Feuerecker B; Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 München, Germany.; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnersite München, 69124 Heidelberg, Germany.; Department of Radiology, University Hospital, LMU Munich, 81377 München, Germany.; Department of Radiology, School of Medicine, Technical University of Munich, 81675 München, Germany., Gafita A; Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA., Langbein T; Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 München, Germany., Tauber R; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, 81675 München, Germany., Seidl C; Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 München, Germany., Bruchertseifer F; European Commission, Joint Research Centre (JRC), 76344 Karlsruhe, Germany., Gschwendt JE; Department of Urology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, 81675 München, Germany., Weber WA; Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 München, Germany.; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnersite München, 69124 Heidelberg, Germany., D'Alessandria C; Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 München, Germany., Morgenstern A; European Commission, Joint Research Centre (JRC), 76344 Karlsruhe, Germany., Eiber M; Department of Nuclear Medicine, School of Medicine, Technical University of Munich, 81675 München, Germany.; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partnersite München, 69124 Heidelberg, Germany. |
| Abstrakt: |
Most Prostate Specific Membrane Antigens (PSMAs) targeting small molecules accumulate in the salivary glands (SGs), raising concerns about SG toxicity, especially after repeated therapies or therapy with 225 Ac-labeled ligands. SG toxicity is assessed clinically by the severity of patient-reported xerostomia, but this parameter can be challenging to objectively quantify. Therefore, we explored the feasibility of using SG volume as a biomarker for toxicity. In 21 patients with late-stage metastatic resistant prostate cancer (mCRPC), the PSMA volume and ligand uptake of SG were analyzed retrospectively before and after two cycles of 177 Lu-PSMA (LuPSMA; cohort A) and before and after one cycle of 225 Ac-PSMA-617 (AcPSMA, cohort B). Mean Volume-SG in cohort A was 59 ± 13 vs. 54 ± 16 mL (-10%, p = 0.4), and in cohort B, it was 50 ± 13 vs. 40 ± 11 mL (-20%, p = 0.007), respectively. A statistically significant decrease in the activity concentration in the SG was only observed in group B (SUV mean : 9.2 ± 2.8 vs. 5.3 ± 1.8, p < 0.0001; vs. A: SUV mean : 11.2 ± 3.3 vs. 11.1 ± 3.5, p = 0.8). SG volume and PSMA-ligand uptake are promising markers to monitor the SG toxicity after a PSMA RLT. |
